BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) announced a poster presentation at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) in Copenhagen, Denmark. The presentation, titled 'Bezisterim Effects on Biological Age, Alzheimer's Epigenetics, and Neurologic Assessments', will showcase clinical data on bezisterim, focusing on its potential impact on longevity and the biological aging process.

Christopher L. Reading, BioVie's Senior VP of Alzheimer's Disease Program, will deliver the presentation on August 27, 2024. The company aims to highlight bezisterim's effects on biological age, gene expression, and measures of aging-related diseases. Detailed data and conclusions will be announced after the public presentation at the conference.

Positive

• BioVie will present clinical data on bezisterim at a prestigious aging research conference
• The presentation will showcase bezisterim's potential impact on biological age and aging-related diseases
• BioVie is advancing research in neurological and neurodegenerative disorders

Negative

• None.

Presentation to showcase potential impact of bezisterim on biological age, gene expression and measures of aging-related diseases from growing body of clinical evidence

CARSON CITY, Nev., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster presentation will be shared at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) being held August 26-30, 2024 in Copenhagen, Denmark.

The presentation “Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments” will provide an overview of clinical data to-date on bezisterim, focusing on various analyses and measurements related to longevity and its ability to affect the biological aging process. The presentation will be given by Christopher L. Reading, BioVie’s Senior Vice President, Alzheimer’s Disease Program, on Tuesday, August 27 from 14:40 - 15:00 CEST.

Details of the presented data and conclusions will be announced once the presentation is made public at the conference.

About Bezisterim        
Bezisterim (NE3107) is an orally bioavailable, BBB-permeable, insulin-sensitizer that is also anti-inflammatory. In addition, it is not immunosuppressive and has a low risk of drug-to-drug interaction. Bezisterim has the potential to reduce symptoms of long COVID, including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFkB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). NE3107 has been shown to modulate the activation of NFkB and thus modulate inflammation.

Bezisterim is being investigated for Alzheimer’s disease (AD) and Parkinson’s disease (PD). BioVie has conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate AD (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from AD. A Phase 2 study of bezisterim in PD (NCT05083260) has been completed, and data presented at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events.

About BioVie Inc.        
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of AD and PD. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. Food and Drug Administration (“FDA”) Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.

Forward-Looking Statements 
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. In this press release, forward-looking statements include, but are not limited to, the potential impact of bezisterim on cognition and function among study participants and topline data from the bezisterim trial. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries: 

Contact:
Bruce Mackle
Managing Director 
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

For Media Inquires
Melyssa Weible
Managing Partner, Elixir Health Public Relations 
Ph: +1 201-723-5705
mweible@elixirhealthpr.com

FAQ

What is BioVie presenting at the ARDD 2024 conference?

BioVie is presenting a poster titled 'Bezisterim Effects on Biological Age, Alzheimer's Epigenetics, and Neurologic Assessments' at the 11th Aging Research and Drug Discovery Meeting (ARDD 2024) in Copenhagen, Denmark on August 27, 2024.

What is the focus of BioVie's (BIVI) presentation on bezisterim?

The presentation focuses on bezisterim's potential impact on biological age, gene expression, and measures of aging-related diseases, showcasing clinical data related to longevity and its ability to affect the biological aging process.

When and where will BioVie (BIVI) present its bezisterim data?

BioVie will present the bezisterim data on Tuesday, August 27, 2024, from 14:40 - 15:00 CEST at the ARDD 2024 conference in Copenhagen, Denmark.

Who will be presenting BioVie's (BIVI) bezisterim data at ARDD 2024?

Christopher L. Reading, BioVie's Senior Vice President of the Alzheimer's Disease Program, will be presenting the bezisterim data at ARDD 2024.